|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest TAB3 may be a useful prognostic biomarker in colorectal cancer and a target for treatment of metastatic colorectal cancer.
|
29290971 |
2017 |
|
Clostridium difficile infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The increased incidence and severity of Clostridium difficile infection (CDI) are thought to result partly from the emergence of the hypervirulent BI/NAP1/027 strain.
|
29174729 |
2018 |
|
Central Diabetes Insipidus
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The increased incidence and severity of Clostridium difficile infection (CDI) are thought to result partly from the emergence of the hypervirulent BI/NAP1/027 strain.
|
29174729 |
2018 |
|
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prevalence of the Clostridium difficile BI/NAP1/027 strain across the United States Veterans Health Administration.
|
29174729 |
2018 |
|
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, ecteinamycin demonstrated potent activity against the toxigenic strain of Clostridium difficile NAP1/B1/027 (MIC = 59 ng/μL), as well as other toxigenic and nontoxigenic C. difficile isolates both in vitro and in vivo.
|
28708379 |
2017 |
|
Clostridium difficile infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of the NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium difficile infection.
|
28645479 |
2017 |
|
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
The NAP1 strain did not increase disease severity, mortality, or recurrence in this study, although the incidence of NAP1-positive healthcare associated-CDI was low.
|
28645479 |
2017 |
|
Clostridium difficile infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
An outbreak of Clostridium difficile infection (CDI) caused by ribotype 027 (B1/NAP1) began in our hospital in November 2014, and produced 141 episodes in the following months.
|
28501926 |
2017 |
|
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
An outbreak of Clostridium difficile infection (CDI) caused by ribotype 027 (B1/NAP1) began in our hospital in November 2014, and produced 141 episodes in the following months.
|
28501926 |
2017 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The transforming growth factor β-activated kinase-binding protein 3 (TAB3) plays a crucial role in modulating cell apoptosis and proliferation in many diseases, including hepatocellular carcinoma, lung cancer, and intracerebral hemorrhage.
|
28462515 |
2017 |
|
Heart Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
In our study, we first investigated the role of TAB3 in ischemia heart diseases.
|
28462515 |
2017 |
|
Myocardial Ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In summary, our findings indicate that the absence of TAB3 plays a harmful role in ischemic heart disease.
|
28462515 |
2017 |
|
Central Diabetes Insipidus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent outbreaks of CDI have been associated with the emergence of hypervirulent strains, such as NAP1/BI/027, many strains of which also produce a third toxin, binary toxin (CDTa and CDTb).
|
28125650 |
2017 |
|
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.
|
28125650 |
2017 |
|
Thiel-Behnke corneal dystrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
We demonstrate, using the Syrian golden hamster model of CDI, that the inclusion of binary toxin components CDTa and CDTb significantly improves the efficacy of the vaccine against challenge with NAP1 strains in comparison to vaccines containing only TcdA and TcdB antigens, while providing comparable efficacy against challenge with the prototypic, non-epidemic strain VPI10463.
|
28125650 |
2017 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Transforming growth factor β-activated protein kinase 1 (TAK1)-binding protein 3 (TAB3) was initially characterized as an adapter protein essential for TAK1 activation in response to IL-1β or TNFα, however, the physiological role of TAB3 in ovarian cancer tumorigenesis is still not fully understood.
|
27651027 |
2016 |
|
ovarian neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Loss of TAB3 expression by shRNA exhibits suppressive bioactivity and increased chemical sensitivity of ovarian cancer cell lines via the NF-κB pathway.
|
27651027 |
2016 |
|
Malignant neoplasm of ovary
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Loss of TAB3 expression by shRNA exhibits suppressive bioactivity and increased chemical sensitivity of ovarian cancer cell lines via the NF-κB pathway.
|
27651027 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Loss of TAB3 expression by shRNA exhibits suppressive bioactivity and increased chemical sensitivity of ovarian cancer cell lines via the NF-κB pathway.
|
27651027 |
2016 |
|
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
The rapid spread of Clostridium difficile NAP1/BI/027 (C. difficile 027) has become one of the leading threats of healthcare-associated infections worldwide.
|
27411304 |
2016 |
|
Diarrhea
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In a 2009 outbreak of C. difficile-associated diarrhea that was recorded in a major Costa Rican hospital, the hypervirulent NAP1 strain (45%) predominated together with a local genotype variant (NAPCR1, 31%).
|
27165560 |
2016 |
|
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparative analysis of the Clostridium difficile BI/NAP1/027 strain R20291 and ClosTron-derived ermB mutants in the hamster infection model are compromised by the clindamycin susceptibility of the parent.Mutants can appear more virulent.
|
26946361 |
2016 |
|
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of Multilocus Sequence Typing and the Xpert C. difficile/Epi Assay for Identification of Clostridium difficile 027/NAP1/BI.
|
26699700 |
2016 |
|
Clostridium difficile infection
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027.
|
26525793 |
2016 |
|
Clostridium; difficile (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical Utility of Laboratory Detection of Clostridium difficile Strain BI/NAP1/027.
|
26511742 |
2016 |